DelveInsight’s, “Becker Muscular Dystrophy Pipeline Insight 2023” report provides comprehensive insights about 8+ companies and 8+ pipeline drugs in the Becker Muscular Dystrophy pipeline landscape. It covers the Becker Muscular pipeline drug profiles, including Becker Muscular clinical trials and nonclinical stage products. It also covers the Becker Muscular therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
To explore more information on the latest breakthroughs in the Becker Muscular Dystrophy Pipeline treatment landscape of the report, click here @ Becker Muscular Dystrophy Pipeline Outlook
Key Takeaways from the Becker Muscular Dystrophy Pipeline Report
For further information, refer to the detailed Becker Muscular Dystrophy Unmet Needs, Becker Muscular Dystrophy Market Drivers, and Becker Muscular Dystrophy Market Barriers, click here for Becker Muscular Dystrophy Ongoing Clinical Trial Analysis
Becker Muscular Dystrophy Overview
Becker muscular dystrophy (BMD) is an inherited condition that causes progressive weakness and wasting of the skeletal and cardiac (heart) muscles. It primarily affects males. The age of onset and rate of progression can vary. Muscle weakness usually becomes apparent between the ages of 5 and 15. The symptoms of Becker muscular dystrophy (BMD) may begin anywhere from childhood to a person’s early 20s.
Request a sample and discover the recent advances in Becker Muscular Dystrophy Ongoing Clinical Trial Analysis and Medications, click here @ Becker Muscular Dystrophy Treatment Landscape
Becker Muscular Dystrophy Emerging Drugs
Givinostat (INN) or gavinostat (originally ITF2357) is a histone deacetylase inhibitor with potential anti-inflammatory, anti-angiogenic, and antineoplastic activities. It is a hydroxamate used in the form of its hydrochloride. Since Givinostat acts on the pathogenetic events downstream of the genetic defects, it is potentially a treatment for the whole DMD and BMD population and to counter the disease pathogenetic events in all muscular districts. The drug is currently being evaluated in Phase II clinical to treat becker muscular dystrophy.
Edgewise Therapeutics Continued to advance a Phase I MAD study of EDG-5506, a small molecule drug candidate designed to arrest muscle fiber breakdown in Duchenne and Becker muscular dystrophy (DMD and BMD).
Dive deep into rich insights for drugs for Becker Muscular Dystrophy Market Drivers and Becker Muscular Dystrophy Market Barriers, click here @ Becker Muscular Dystrophy Unmet Needs and Analyst Views
Becker Muscular Dystrophy Pipeline Therapeutics Assessment
There are approx. 8+ key companies which are developing the therapies for Becker Muscular Dystrophy. The companies which have their Becker Muscular Dystrophy drug candidates in the most advanced stage, i.e. Phase II include, Italfarmaco.
Scope of the Becker Muscular Dystrophy Pipeline Report
Got Queries? Find out the related information on Becker Muscular Dystrophy Mergers and acquisitions, Becker Muscular Dystrophy Licensing Activities @ Becker Muscular Dystrophy Emerging Drugs, and Recent Trends
Table of Content
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting-services